Policy Finalized Intact

HHS and FDA proceed with a national framework that legalizes peptide compounding with relatively broad access through 503A pharmacies and 503B outsourcing facilities. This is the most likely path because the FDA panel already backed compounding in July and the submitted policy signals interagency alignment.

Each figure is the modeled move of the S&P 500 if the outcome occurs. For information only. Not investment advice.